Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of plecanatide in IBS-C
NCT02706483Phase 3Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Jan 2016
- Primary completion
- May 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of plecanatide in irritable bowel syndrome (IBS), sponsored by Valeant Pharmaceuticals. Started Jan 2016; status: completed.
02
Drugs
plecanatide
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT02706483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02706483.